BioSpace News Archive

Bioscience employment rose in 41 states, though not in California, according to a new report from the Biotechnology Innovation Organization and the Council of State Bioscience Associations.

The cessation of manufacturing activities follows a Sun Pharma recall and reports that regulators found fault with the company’s quality system.

Two-year agreement and approximately US$198,000 in potential purchases while opening established UK first-aid, medical-supply, workplace and education channels Highlights • Definitive agreement signed October 28, 2026 appoints Poole Bay Holdings Ltd. as exclusive UK distributor of VIVI Epi™ for an initial 24-month term, subject to UK regulatory requirements. • Contractual minimum purchase to maintain exclusivity. The initial two-year minimum volumes represent approximately US$198,000 in potential purchases. • Poole Bay Holdings reports 20 specialist e-commerce sites and more than 30,000 products, spanning first-aid, medical, health and safety, and workplace supplies. • Poole Bay has a network of 15,000 schools across the UK, and will be providing VIVI Epi to these locations • UK Food Standards Agency research estimates approximately 2.4 million adults have a clinically confirmed food allergy, highlighting the scale of allergy-management needs [1]. • The agreement provides for launch sampling, planned promotional activity and a framework to pursue institutional and consumer channels, subject to registrations and market adoption.

Debtor-in-process financing up to $55 million could keep the lights on at Karyopharm Therapeutics for its multiple myeloma and myelofibrosis programs as the biotech waits to see if its union with Ayrmid will go through.